Malignant Paraganglioma Clinical Trial
Official title:
A Phase 2 Study of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma. Anlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PRIMARY OBJECTIVES: To determine the anti-tumor activity of anlotinib hydrochloride (Objective Response rate,ORR) in patients with metastatic pheochromocytomas or paragangliomas. SECONDARY OBJECTIVES: I. To assess safety profile of anlotinib. II. To assess progression-free survival time. III. To assess disease control rate. OUTLINE: Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo urine and blood sample collection, imaging examinations at baseline and periodically during study. After completion of study therapy, patients are followed up every 3-6 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02592356 -
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
|
N/A | |
| Completed |
NCT03008369 -
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT01155258 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 |